Regorafenib is a pyridinecarboxamide formed by the condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. It is used in the treatment of metastatic colorectal cancer in patients who have undergone prior chemotherapy, anti-EGFR, or anti-VEGF therapy. Regorafenib functions as an antineoplastic agent, tyrosine kinase inhibitor, and hepatotoxic agent. It is classified as an aromatic ether, pyridinecarboxamide, monochlorobenzenes, (trifluoromethyl)benzenes, monofluorobenzenes, and phenylurea.
